1. Cyhoeddwyd

   Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.

   Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Tach 2007, Yn: Value in Health. 10, 6, t. 498-509

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

2. Cyhoeddwyd

   Statistical comments are unfounded.

   Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Maw 2008, Yn: Value in Health. 11, 2, t. 346

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

3. Cyhoeddwyd

   The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

   Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Mai 2008.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. Cyhoeddwyd

   Economic evaluation of on-demand maintenance therapy with proton pump inhibitors in patients with symptomatic gastroesophageal reflux disease - a Monte-Carlo analysis for Italy

   Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Hyd 2004.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

5. Cyhoeddwyd

   All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

6. Cyhoeddwyd

   The British antibiotic and silver-impregnated catheters for ventriculoperitoneal shunts multi-centre randomised controlled trial (the BASICS trial): study protocol

   Hughes, D., Jenkinson, M. D., Gamble, C., Hartley, J. C., Hickey, H., Hughes, D. A., Blundell, M., Griffiths, M. J., Solomon, T. & Malluci, C. L., 3 Ion 2014, Yn: Trials. 15, 14

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   Improving Outcomes for People with Skin Tumours including Melanoma: Analysis of the Potential Economic Impact of the Guidance.

   Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 21 Chwef 2006, Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

8. Cyhoeddwyd

   Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

   Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Medi 2003.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

9. Cyhoeddwyd

   Use of PK-PD modelling to predict the impact of non-compliance

   Hughes, D. & Hughes, D. A., 1 Tach 2003.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

10. Cyhoeddwyd

    Multiple imputation of multiple multi-item scales when a full imputation model is infeasible

    Hughes, D., Plumpton, C. O., Morris, T., Hughes, D. A. & White, I. R., 26 Ion 2016, Yn: BMC Research Notes. 9, 45, t. 1-15

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

11. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Meh 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

12. Cyhoeddwyd

    Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?

    Hughes, D., Hughes, D. A., Bayoumi, A. M. & Pirmohamed, M., 1 Awst 2007, Yn: Clinical Pharmacology and Therapeutics. 82, 2, t. 123-127

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

13. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

14. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment

    Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Maw 2008

    Allbwn ymchwil: Ffurf annhestunol › Safe Gwe / Cyhoeddiad Gwe

15. Cyhoeddwyd

    Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group

    Hughes, D., Linck, P. G., Hiligsmann, M., Salas, M., Hughes, D. A., Manias, E., Gwadry-Sridhar, F. H., Linck, P. & Cowell, W., 1 Rhag 2013, Yn: Osteoporosis International. 24, 12, t. 2907-2918

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

16. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Gorff 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

17. Cyhoeddwyd

    Drugs for exceptionally rare diseases: do they deserve special status for funding?

    Hughes, D., Tunnage, B. & Yeo, S. T., 1 Tach 2005, Yn: QJM - An International Journal of Medicine. 98, 11, t. 829-836

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

18. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

19. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A109

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

20. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

21. Cyhoeddwyd

    The Population Pharmacokinetics of R and S-Warfarin: Effect of Genetic and Clinical Factors

    Hughes, D., Lane, S., Al-Zubiedi, S., Hatch, E., Matthews, I., Jorgensen, A. L., Deloukas, P., Daly, A. K., Aarons, L., Ogungbenro, K., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Ion 2012, Yn: British Journal of Clinical Pharmacology. 73, 1, t. 66-76

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

22. Cyhoeddwyd

    Decision-Makers’ Preferences for Approving New Medicines in Wales: A Discrete-Choice Experiment with Assessment of External Validity

    Hughes, D., Linley, W. G. & Hughes, D. A., 1 Ebr 2013, Yn: Pharmacoeconomics. 31, 4, t. 345-355

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

23. Cyhoeddwyd

    Climate influences on the cost-effectiveness of vector-based interventions against malaria in elimination scenarios

    Hughes, D., Parham, P. E. & Hughes, D. A., 16 Chwef 2015, Yn: Philosophical Transactions B: Biological Sciences. 370, 1665

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

24. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 749

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

25. Cyhoeddwyd

    Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.

    Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Ion 2004, Yn: Drug Safety. 27, 8, t. 535-554

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

26. Cyhoeddwyd

    Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Ion 2004, Yn: Pharmacoeconomics. 22, 16, t. 1047-1059

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

27. Cyhoeddwyd

    Pharmacogenetic tests: the need for a level playing field

    Hughes, D., Pirmohamed, M. & Hughes, D. A., 1 Ion 2013, Yn: Nature Reviews Drug Discovery. 12, 3-4

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

28. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

29. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

30. Cyhoeddwyd

    Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population

    Hughes, D., Mulhern, B., Rowen, D., Snape, D., Jacoby, A., Marson, T., Hughes, D. A., Baker, G. & Brazier, J., 1 Gorff 2014, Yn: Epilepsy and Behavior. 36, t. 12-17

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

31. Cyhoeddwyd

    Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

    Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

32. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

33. Cyhoeddwyd

    Pharmacoeconomic evaluations in Ireland, Scotland and Wales: A Celtic perspective on pharmaceutical assessment

    Hughes, D., Hughes, D. A., Drummond, M., Tolley, K. & Ryan, M., 1 Hyd 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

34. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

    Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Meh 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

35. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

36. Cyhoeddwyd

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

37. Cyhoeddwyd

    Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

    Hughes, D., Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A. P., Hornberger, J., Hughes, D. A., Li, T., Malone, D., Payne, K., Siebert, U., Towse, A., Veenstra, D. & Watkins, J., 1 Rhag 2012, Yn: Value in Health. 15, 8, t. 1162-1171

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

38. Cyhoeddwyd

    Rationing of drugs for rare diseases

    Hughes, D. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

39. Cyhoeddwyd

    Less is more: Medicines that require less frequent administration improve adherence, but are they better?

    Hughes, D. & Hughes, D. A., 1 Ion 2006, Yn: Pharmacoeconomics. 24, 3, t. 211-213

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

40. Cyhoeddwyd

    Rationing of drugs for rare diseases.

    Hughes, D. & Hughes, D. A., 1 Ion 2006, Yn: Pharmacoeconomics. 24, 4, t. 315-316

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

41. Cyhoeddwyd

    The economics of evergreening.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

42. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

43. Cyhoeddwyd

    A systematic review and empirical analysis of the relation between dose and duration of drug action.

    Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Ion 2009, t. TP40.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

44. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

45. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

46. Cyhoeddwyd

    Orphan drugs revisited: author's response.

    Hughes, D. & Hughes, D. A., 1 Mai 2006, Yn: Quarterly Journal of Medicine. 99, 5, t. 350-351

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

47. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Maw 2010, Yn: Clinical Pharmacology and Therapeutics. 87, 3, t. 257-261

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

48. Cyhoeddwyd

    Understanding medication compliance and persistence from an economics perspective

    Hughes, D., Elliot, R. A., Shinogle, J. A., Peele, P., Bhosle, M. & Hughes, D. A., 1 Ion 2008, Yn: Value in Health. 11, 4, t. 600-610

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

49. Cyhoeddwyd

    Welsh Health Economics Network (WHEN): Scoping Report.

    Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Ion 2005, 2005 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

50. Cyhoeddwyd

    Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.

    Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn